Literature DB >> 32494066

Landscape and function of multiple mutations within individual oncogenes.

Yuki Saito1,2, Junji Koya1, Mitsugu Araki3, Yasunori Kogure1, Sumito Shingaki1, Mariko Tabata1,4, Marni B McClure1, Kota Yoshifuji1,5, Shigeyuki Matsumoto6, Yuta Isaka7, Hiroko Tanaka8, Takanori Kanai2, Satoru Miyano8, Yuichi Shiraishi9, Yasushi Okuno3, Keisuke Kataoka10.   

Abstract

Sporadic reports have described cancer cases in which multiple driver mutations (MMs) occur in the same oncogene1,2. However, the overall landscape and relevance of MMs remain elusive. Here we carried out a pan-cancer analysis of 60,954 cancer samples, and identified 14 pan-cancer and 6 cancer-type-specific oncogenes in which MMs occur more frequently than expected: 9% of samples with at least one mutation in these genes harboured MMs. In various oncogenes, MMs are preferentially present in cis and show markedly different mutational patterns compared with single mutations in terms of type (missense mutations versus in-frame indels), position and amino-acid substitution, suggesting a cis-acting effect on mutational selection. MMs show an overrepresentation of functionally weak, infrequent mutations, which confer enhanced oncogenicity in combination. Cells with MMs in the PIK3CA and NOTCH1 genes exhibit stronger dependencies on the mutated genes themselves, enhanced downstream signalling activation and/or greater sensitivity to inhibitory drugs than those with single mutations. Together oncogenic MMs are a relatively common driver event, providing the underlying mechanism for clonal selection of suboptimal mutations that are individually rare but collectively account for a substantial proportion of oncogenic mutations.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32494066     DOI: 10.1038/s41586-020-2175-2

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   69.504


  42 in total

1.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Authors:  Susumu Kobayashi; Titus J Boggon; Tajhal Dayaram; Pasi A Jänne; Olivier Kocher; Matthew Meyerson; Bruce E Johnson; Michael J Eck; Daniel G Tenen; Balázs Halmos
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

2.  A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.

Authors:  Shinji Kohsaka; Masaaki Nagano; Toshihide Ueno; Yoshiyuki Suehara; Takuo Hayashi; Naoko Shimada; Kazuhisa Takahashi; Kenji Suzuki; Kazuya Takamochi; Fumiyuki Takahashi; Hiroyuki Mano
Journal:  Sci Transl Med       Date:  2017-11-15       Impact factor: 17.956

Review 3.  Lessons from the cancer genome.

Authors:  Levi A Garraway; Eric S Lander
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

4.  Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Charles D Blanke; George D Demetri; Heikki Joensuu; Peter J Roberts; Burton L Eisenberg; Margaret von Mehren; Christopher D M Fletcher; Katrin Sandau; Karen McDougall; Wen-bin Ou; Chang-Jie Chen; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2006-09-05       Impact factor: 44.544

Review 5.  Cancer genome landscapes.

Authors:  Bert Vogelstein; Nickolas Papadopoulos; Victor E Velculescu; Shibin Zhou; Luis A Diaz; Kenneth W Kinzler
Journal:  Science       Date:  2013-03-29       Impact factor: 47.728

6.  Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

Authors:  William Pao; Vincent A Miller; Katerina A Politi; Gregory J Riely; Romel Somwar; Maureen F Zakowski; Mark G Kris; Harold Varmus
Journal:  PLoS Med       Date:  2005-02-22       Impact factor: 11.069

7.  Oncogenic PIK3CA promotes cellular stemness in an allele dose-dependent manner.

Authors:  Ralitsa R Madsen; Rachel G Knox; Wayne Pearce; Saioa Lopez; Betania Mahler-Araujo; Nicholas McGranahan; Bart Vanhaesebroeck; Robert K Semple
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-04       Impact factor: 11.205

8.  Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.

Authors:  Junichi Soh; Naoki Okumura; William W Lockwood; Hiromasa Yamamoto; Hisayuki Shigematsu; Wei Zhang; Raj Chari; David S Shames; Ximing Tang; Calum MacAulay; Marileila Varella-Garcia; Tõnu Vooder; Ignacio I Wistuba; Stephen Lam; Rolf Brekken; Shinichi Toyooka; John D Minna; Wan L Lam; Adi F Gazdar
Journal:  PLoS One       Date:  2009-10-14       Impact factor: 3.240

9.  Universal Patterns of Selection in Cancer and Somatic Tissues.

Authors:  Iñigo Martincorena; Keiran M Raine; Moritz Gerstung; Kevin J Dawson; Kerstin Haase; Peter Van Loo; Helen Davies; Michael R Stratton; Peter J Campbell
Journal:  Cell       Date:  2017-10-19       Impact factor: 41.582

10.  Mutational heterogeneity in cancer and the search for new cancer-associated genes.

Authors:  Michael S Lawrence; Petar Stojanov; Paz Polak; Gregory V Kryukov; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Chip Stewart; Craig H Mermel; Steven A Roberts; Adam Kiezun; Peter S Hammerman; Aaron McKenna; Yotam Drier; Lihua Zou; Alex H Ramos; Trevor J Pugh; Nicolas Stransky; Elena Helman; Jaegil Kim; Carrie Sougnez; Lauren Ambrogio; Elizabeth Nickerson; Erica Shefler; Maria L Cortés; Daniel Auclair; Gordon Saksena; Douglas Voet; Michael Noble; Daniel DiCara; Pei Lin; Lee Lichtenstein; David I Heiman; Timothy Fennell; Marcin Imielinski; Bryan Hernandez; Eran Hodis; Sylvan Baca; Austin M Dulak; Jens Lohr; Dan-Avi Landau; Catherine J Wu; Jorge Melendez-Zajgla; Alfredo Hidalgo-Miranda; Amnon Koren; Steven A McCarroll; Jaume Mora; Brian Crompton; Robert Onofrio; Melissa Parkin; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Charles W M Roberts; Jaclyn A Biegel; Kimberly Stegmaier; Adam J Bass; Levi A Garraway; Matthew Meyerson; Todd R Golub; Dmitry A Gordenin; Shamil Sunyaev; Eric S Lander; Gad Getz
Journal:  Nature       Date:  2013-06-16       Impact factor: 49.962

View more
  28 in total

Review 1.  Allostery, and how to define and measure signal transduction.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  Biophys Chem       Date:  2022-01-29       Impact factor: 2.352

Review 2.  Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment.

Authors:  Martyna Filipska; Rafael Rosell
Journal:  Mol Oncol       Date:  2021-05-26       Impact factor: 6.603

Review 3.  Anticancer drug resistance: An update and perspective.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  Drug Resist Updat       Date:  2021-12-16       Impact factor: 18.500

4.  Drugging multiple same-allele driver mutations in cancer.

Authors:  Ruth Nussinov; Mingzhen Zhang; Ryan Maloney; Hyunbum Jang
Journal:  Expert Opin Drug Discov       Date:  2021-03-26       Impact factor: 7.050

5.  Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases.

Authors:  Richard S P Huang; James Haberberger; Kimberly McGregor; Douglas A Mata; Brennan Decker; Matthew C Hiemenz; Mirna Lechpammer; Natalie Danziger; Kelsie Schiavone; James Creeden; Ryon P Graf; Roy Strowd; Glenn J Lesser; Evangelia D Razis; Rupert Bartsch; Athina Giannoudis; Talvinder Bhogal; Nancy U Lin; Lajos Pusztai; Jeffrey S Ross; Carlo Palmieri; Shakti H Ramkissoon
Journal:  Oncologist       Date:  2021-06-23

Review 6.  Targeting SHIP1 and SHIP2 in Cancer.

Authors:  Chiara Pedicone; Shea T Meyer; John D Chisholm; William G Kerr
Journal:  Cancers (Basel)       Date:  2021-02-20       Impact factor: 6.639

7.  FSCN1 Promotes Radiation Resistance in Patients With PIK3CA Gene Alteration.

Authors:  Sisi Li; Xiao-Ting Huang; Meng-Yao Wang; Dong-Ping Chen; Ming-Yi Li; Yan-Yi Zhu; Yi Yu; Lu Zheng; Bin Qi; Jin-Quan Liu
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

Review 8.  PI3K inhibitors are finally coming of age.

Authors:  Bart Vanhaesebroeck; Matthew W D Perry; Jennifer R Brown; Fabrice André; Klaus Okkenhaug
Journal:  Nat Rev Drug Discov       Date:  2021-06-14       Impact factor: 112.288

9.  Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.

Authors:  Ariella B Hanker; Benjamin P Brown; Jens Meiler; Arnaldo Marín; Harikrishna S Jayanthan; Dan Ye; Chang-Ching Lin; Hiroaki Akamatsu; Kyung-Min Lee; Sumanta Chatterjee; Dhivya R Sudhan; Alberto Servetto; Monica Red Brewer; James P Koch; Jonathan H Sheehan; Jie He; Alshad S Lalani; Carlos L Arteaga
Journal:  Cancer Cell       Date:  2021-06-24       Impact factor: 38.585

10.  Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer.

Authors:  Ikuko Takeda Nakamura; Shinji Kohsaka; Masachika Ikegami; Hiroshi Ikeuchi; Toshihide Ueno; Kunhua Li; Tyler S Beyett; Takafumi Koyama; Toshio Shimizu; Noboru Yamamoto; Fumiyuki Takahashi; Kazuhisa Takahashi; Michael J Eck; Hiroyuki Mano
Journal:  NPJ Precis Oncol       Date:  2021-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.